Takeda Pharmaceutical Company Ltd. (TAK) reported its fourth-quarter results on Wednesday, and while revenue came in a bit light, the real story is what's coming next. The Japanese drugmaker posted sales of $6.98 billion (1.094 trillion yen), missing the $7.05 billion analysts were looking for. But on the bottom line, Takeda delivered adjusted earnings of 28 cents per ADR (89 yen per share), beating the consensus estimate of 21 cents.
CFO Milano Furuta struck a confident tone, saying the company delivered "solid profit and cash flow through disciplined cost control" in fiscal 2025, despite some revenue headwinds. Looking ahead, he said: "In FY2026, we will continue to focus on transforming operations and protecting profitability while delivering successful launches and advancing our pipeline. Strong cash flow generation and deleveraging will support long-term investment for growth acceleration and ensure competitive returns for our shareholders."
Investors are paying close attention to Takeda's late-stage pipeline, which the company says could support multiple regulatory approvals in the U.S. and other markets during fiscal 2026 and 2027. The most advanced candidate is oveporexton, a potential first-in-class orexin agonist for narcolepsy type 1, which has already received Priority Review from the FDA. Takeda is preparing for a U.S. launch.
Also in the pipeline is rusfertide, a hepcidin mimetic for polycythemia vera, which has also snagged FDA Priority Review. And then there's zasocitinib, an oral psoriasis treatment, which is expected to move toward regulatory filing in 2026, with a commercial launch targeted for the first half of 2027.
For fiscal 2026, Takeda is forecasting adjusted earnings of 31 cents per share (472 yen) and sales of $29.58 billion (4.64 trillion yen). Shares were up 0.24% at $16.47 at the time of publication.
